Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKEF) (‘Alkane’ or ‘the Company’) is pleased to announce the latest ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ALK receptor tyrosine kinase (RTK) is ...

Panelists discuss how strategic nursing coordination and effective communication support timely and comprehensive biomarker testing for newly diagnosed NSCLC patients. This segment focuses on the ...

Real-world uptake of ALK biomarker testing appears to be underutilized since the FDA’s 2024 approval of adjuvant alectinib. Research in other disease states has shown that it is not uncommon for ...

Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Purpose: The aim of this study was to investigate the prognostic value of the abnormal expression of anaplastic lymphoma kinase (ALK) protein in patients with small cell lung cancer (SCLC) based on ...

Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.

Please provide your email address to receive an email when new articles are posted on . AccuTest provides smaller tine lengths and diameters, which improve precision and lessen discomfort. AccuTest ...